The FDA approved Pfizer and BioNTech’s 2026–27 COMIRNATY XFG COVID-19 vaccine for adults 65 and older and people ages 5–64 with high-risk conditions. The article says the update may protect recurring seasonal revenue, but normalized booster demand limits growth.
The companies announced the approval on Aug. 27. According to the article, it was based on clinical, real-world and manufacturing data showing strong immune responses against circulating strains and aligned with FDA strain guidance for fall 2026.
The article characterizes the approval as a defense of recurring revenue rather than a growth engine, citing COVID booster demand’s normalization from pandemic peaks. It says seasonal cash flow could support Pfizer’s non-COVID pipeline and debt repayment, while BioNTech’s approval helps preserve liquidity as it advances oncology trials. Lower vaccination rates and pipeline setbacks remain risks.
